• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Kinnate Biopharma Inc.

    11/27/23 4:47:20 PM ET
    $KNTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNTE alert in real time by email
    SC 13G 1 p1115237sc13g.htm

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )* 

     

    Kinnate Biopharma Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    49705R105

    (CUSIP Number)

     

    November 15, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 pages 
     

     

    CUSIP No. 49705R105

     

     

    13G Page 2 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP 

    2 Check the Appropriate Box if a Member of a Group*
    (
    a) ¨
    (b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,965,715

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    2,965,715

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,965,715

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    6.3% 

    12

    type of reporting person

     

    pN 

     

     Page 2 of 8 pages 
     

     

    CUSIP No. 49705R105

     

     

    13G Page 3 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC 

    2 Check the Appropriate Box if a Member of a Group*
    (
    a) ¨
    (b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,965,715

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    2,965,715

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,965,715

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    6.3% 

    12

    type of reporting person

     

    OO 

     

     Page 3 of 8 pages 
     

     

    CUSIP No. 49705R105

     

     

    13G Page 4 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang 

    2 Check the Appropriate Box if a Member of a Group*
    (
    a) ¨
    (b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,965,715

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    2,965,715

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,965,715

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    6.3% 

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 pages 
     

     

    Item 1(a).Name of Issuer:

     

    Kinnate Biopharma Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    103 Montgomery Street, Suite 150, The Presidio of San Francisco, San Francisco, CA 94129

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number 49705R105

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 2,965,715 of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 2,965,715 of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 2,965,715 of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 pages 
     

     

    The percentages used herein are based on 47,112,698 shares of Common Stock outstanding as of November 3, 2023, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on November 9, 2023.

     

    (b)Percent of Class:

     

    Tang Capital Partners 6.3%
    Tang Capital Management 6.3%
    Kevin Tang 6.3%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 2,965,715 shares
    Tang Capital Management 2,965,715 shares
    Kevin Tang 2,965,715 shares
       
    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 2,965,715 shares
    Tang Capital Management 2,965,715 shares
    Kevin Tang 2,965,715 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 pages 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 

     

     

    Date:   November 27, 2023  

     

     

    TANG CAPITAL PARTNERS, LP  
         
    By: Tang Capital Management, LLC, its General Partner  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

     

    Get the next $KNTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNTE

    DatePrice TargetRatingAnalyst
    11/17/2022$35.00 → $11.00Buy → Hold
    Stifel
    7/28/2022$33.00Buy
    H.C. Wainwright
    9/27/2021$46.00Buy
    Jefferies
    9/23/2021$32.00Buy
    Stifel
    7/13/2021Outperform
    William Blair
    More analyst ratings

    $KNTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kinnate BioPharma downgraded by Stifel with a new price target

      Stifel downgraded Kinnate BioPharma from Buy to Hold and set a new price target of $11.00 from $35.00 previously

      11/17/22 7:29:36 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Kinnate BioPharma with a new price target

      H.C. Wainwright initiated coverage of Kinnate BioPharma with a rating of Buy and set a new price target of $33.00

      7/28/22 7:41:00 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Kinnate Biopharma with a new price target

      Jefferies initiated coverage of Kinnate Biopharma with a rating of Buy and set a new price target of $46.00

      9/27/21 5:06:44 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XOMA Corporation Announces Closing of Tender Offer

      EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate p

      4/3/24 9:00:00 AM ET
      $KNTE
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

      EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (("Kinnate", NASDAQ:KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share (together with the base price, the Cash Amount), plus one non-tradeable contingent value right ("CVR") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds from any

      3/19/24 4:05:00 PM ET
      $KNTE
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

      Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors.  CASTRES, France and SAN FRANCISCO, March 1, 2024 /CNW/ -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, and Pierre Fabre Méd

      3/1/24 8:35:00 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNTE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Kinnate Biopharma Inc.

      15-12G - Kinnate Biopharma Inc. (0001797768) (Filer)

      4/17/24 4:01:50 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Kinnate Biopharma Inc.

      S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)

      4/3/24 5:28:02 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Kinnate Biopharma Inc.

      S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)

      4/3/24 5:25:55 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNTE
    Leadership Updates

    Live Leadership Updates

    See more
    • Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director

      SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023. Ms. DeSimone brings more than forty years of global business expertise in life sciences to Kinnate's board of directors. Dean J. Mitchell, chairman of the Kinnate board of directors, commented, "I am honored to welcome Jill to the Kinnate board of directors. She is an ideal fit given her breadth of experience as a global business leader for multi-billion-dollar oncology medicines, strategic leade

      1/26/23 4:05:00 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results

      Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors Strengthened management team and Board of Directors with key appointments Ended the quarter with cash, cash equivalents and investments of $365.1 million, exclusive of $35.0 million in its China joint venture SAN FRANCISCO and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended June 30, 2021. The company also announc

      8/16/21 4:05:00 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors

      SAN FRANCISCO and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the appointment of Helen Sabzevari, Ph.D. to its Board of Directors. Dr. Sabzevari is a global thought leader who is internationally recognized for her work in the field of oncology. Her career-long efforts have helped bridge the gap between cancer cell biology and immunology, bringing these disciplines together to understand how the immune system and cancer cells interact on the broader system level and for

      6/28/21 8:00:00 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $KNTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Tananbaum James B. returned 13,718,311 shares to the company (SEC Form 4)

      4 - Kinnate Biopharma Inc. (0001797768) (Issuer)

      4/5/24 4:55:52 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Krishnamohan Neha returned 64,087 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Kinnate Biopharma Inc. (0001797768) (Issuer)

      4/5/24 4:55:33 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mitchell Dean J

      4 - Kinnate Biopharma Inc. (0001797768) (Issuer)

      4/5/24 4:55:38 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Kinnate Biopharma Inc. (Amendment)

      SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)

      4/5/24 4:15:42 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Kinnate Biopharma Inc. (Amendment)

      SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)

      2/22/24 4:39:18 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Kinnate Biopharma Inc. (Amendment)

      SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)

      2/21/24 4:11:40 PM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNTE
    Financials

    Live finance-specific insights

    See more
    • XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

      EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (("Kinnate", NASDAQ:KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share (together with the base price, the Cash Amount), plus one non-tradeable contingent value right ("CVR") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds from any

      3/19/24 4:05:00 PM ET
      $KNTE
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

      EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ:KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with the Base Price, the Cash Amount) at the closing of the merger plus a non-transferable contingent value right (CVR), representing the right to receive 85% of the net proceeds from any out license or sale of the Kinnate programs effected within one year of closing of the merger or 100% of the net proceeds from any out license or sale executed prior to the closing. "This

      2/16/24 8:00:00 AM ET
      $KNTE
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care